Abstract | AIMS: METHODS: This was a multi-center, randomized, rater-blinded, parallel-group, flexible-dose study. Forty-five hospitalized patients with moderate-to-severe manic, bipolar disorder (DSM-IV) were randomly assigned to a zotepine or a haloperidol 4-week treatment group. RESULTS: There was no significant between-group difference in the Young Mania Rating Scale total scores between the zotepine and haloperidol groups (-23.7 + or - 12.1 vs -22.3 + or - 11.0, respectively). The adverse events in both groups were mild to moderate. The haloperidol group reported a higher incidence of treatment-related adverse events, especially parkinsonism and akathisia, compared to the zotepine group. Serum uric acid decreased more in the zotepine group than in the haloperidol group. CONCLUSION: In combination with a mood stabilizer, zotepine appears to be as effective as haloperidol in treating moderate-to-severe mania in the acute phase, but has the advantages of lowering hyperuricemia and fewer extrapyramidal side-effects. Double-blinded studies with larger sample sizes are warranted to confirm these findings.
|
Authors | Hung-Yu Chan, Shaw-Hua Jou, Yeong-Yuh Juang, Ching-Jui Chang, Jiahn-Jyh Chen, Chiung-Hsu Chen, Nan-Ying Chiu |
Journal | Psychiatry and clinical neurosciences
(Psychiatry Clin Neurosci)
Vol. 64
Issue 2
Pg. 162-9
(Apr 2010)
ISSN: 1440-1819 [Electronic] Australia |
PMID | 20447012
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Antimanic Agents
- Antipsychotic Agents
- Dibenzothiepins
- Haloperidol
- zotepine
|
Topics |
- Adult
- Aged
- Antimanic Agents
(therapeutic use)
- Antipsychotic Agents
(therapeutic use)
- Bipolar Disorder
(drug therapy)
- Dibenzothiepins
(therapeutic use)
- Drug Administration Schedule
- Female
- Haloperidol
(therapeutic use)
- Humans
- Intention to Treat Analysis
- Male
- Middle Aged
- Patient Selection
- Severity of Illness Index
- Single-Blind Method
- Treatment Outcome
|